RxDoctor Payments Data

Jacob Kelly, MD

Advanced Heart Failure and Transplant Cardiology · Anchorage, AKNPI 1851551949

Payments from drug & device makers

$650,001in general payments, 2019–2025

Across 205 payments — averaging $3170.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$453K
  • Amgen$171K
  • Eli Lilly$13K
  • Actelion Pharmaceuticals US, Inc.$6K
  • Akcea Therapeutics, Inc.$4K
  • Abbott$765
  • plus $3K from 20 others
$2,639in research payments, 2019–2025

Across 1 payment — averaging $2638.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$3K

What the payments were for

  • Speaking & faculty fees$35,46082%
  • Travel & lodging$2,4036%
  • Food & beverage$5,14512%
  • Education$200%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few advanced heart failure and transplant cardiology providers in Alaskato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$706,081
Medicare patients
2,042
Services billed
14,321

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan370$419,698
EliquisApixaban266$393,008
JardianceEmpagliflozin239$282,285
VyndamaxTafamidis13$266,514
FarxigaDapagliflozin Propanediol60$92,873
XareltoRivaroxaban66$78,245
Repatha SureclickEvolocumab30$35,123
WegovySemaglutide14$20,243
OzempicSemaglutide18$18,990
Eplerenone70$10,315
Metoprolol Succinate398$9,362
Spironolactone523$6,000
Sildenafil Citrate13$4,631
Atorvastatin Calcium270$4,098
Dabigatran EtexilateDabigatran Etexilate Mesylate21$3,261

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Vyndamax$135$659,521279 claims
NovartisEntresto$452,803$419,698370 claims
Boehringer IngelheimJardiance, Pradaxa$41$284,250276 claims
AstraZenecaFarxiga$19$92,87360 claims
Johnson & JohnsonXarelto$38$78,24566 claims
Novo NordiskWegovy, Ozempic$125$39,23332 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Alaskaon file to place this against a meaningful peer group, so we don't.

Where these figures come from

Is this you, or does something look wrong? →